Skip to Content
Merck
CN

Pyrrolidinyl phenylurea derivatives as novel CCR3 antagonists.

Bioorganic & medicinal chemistry letters (2012-10-11)
Aiko Nitta, Yosuke Iura, Hideki Inoue, Ippei Sato, Koichiro Morihira, Hirokazu Kubota, Tatsuaki Morokata, Makoto Takeuchi, Mitsuaki Ohta, Shin-ichi Tsukamoto, Takayuki Imaoka, Toshiya Takahashi
ABSTRACT

Optimization starting with our lead compound 1 (IC(50)=4.9 nM) led to the identification of pyrrolidinyl phenylurea derivatives. Further modification toward improvement of the bioavailability provided (R)-1-(1-((6-fluoronaphthalen-2-yl)methyl)pyrrolidin-3-yl)-3-(2-(2-hydroxyethoxy)phenyl)urea 32 (IC(50)=1.7 nM), a potent and orally active CCR3 antagonist.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Pyrrolidine, ≥99.0%
Sigma-Aldrich
Pyrrolidine, ≥99.5%, purified by redistillation
Sigma-Aldrich
Pyrrolidine, 99%
Sigma-Aldrich
Pyrrolidine, FG